The transition from pediatric to adult headache care creates an opportunity for changes in care, although the nature of these changes has not been previously explored. We aim to describe the changes in management during this transition period.
Methods
A retrospective chart review was conducted on 80 patients who transitioned from pediatric neurology to adult headache clinic within the span of 1 year. The demographics, diagnoses, and treatment regimens were analyzed.
Results
On average, patients held their first adult headache clinic visit 118 days following their last pediatric visit. More than half of patients experienced changes in either diagnosis or treatment during transition.
Conclusion
This research emphasizes the significant influence of care transitions on the management of patients with primary headache disorders.
OnofriAPensatoURosignoliC, et al.Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis. J Headache Pain. 2023;24:8.
2.
LiptonRBManackARicciJACheeETurkelCCWinnerP. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011;51:693-706.
3.
AntonaciFVoiticovschi-IosobCDi StefanoALGalliFOzgeABalottinU. The evolution of headache from childhood to adulthood: a review of the literature. J Headache Pain. 2014;15:15.
4.
OrrSLGelfandAAHranilovichJ, et al.The development of the medical transfer packet for transition of care of the pediatric patient with headache. Headache. 2020;60:2589-2591.
5.
TiltonAHDe GusmaoCM. Transition from pediatric to adult neurologic care. Continuum (Minneap Minn). 2018;24:276-287.
6.
von ElmEAltmanDGEggerMPocockSJGøtzschePCVandenbrouckeJP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol.2008;61:344-349.
7.
VictorTWHuXCampbellJCBuseDCLiptonRB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30:1065-1072.
8.
O’BrienHLCohenJM. Young adults with headaches: the transition from adolescents to adults. Headache. 2015;55:1404-1409.
9.
BilleB. A 40-year follow-up of school children with migraine. Cephalalgia. 1997;17:488-491.
10.
KernickDStapleySCampbellJHamiltonW. What happens to new-onset headache in children that present to primary care? A case-cohort study using electronic primary care records. Cephalalgia. 2009;29:1311-1316.
11.
LoboRWangMLoboSBahraA. Time to retire ‘new daily persistent headache’: mode of onset of chronic migraine and tension-type headache. Cephalalgia. 2022;42:385-395.
12.
OskouiMPringsheimTHoller-ManaganY, et al.Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93:487-499.
13.
ACGME Program Requirements for Graduate Medical Education in Neurology. 2023.
14.
AhmedZAFaulknerLR. Headache education in adult neurology residency: a survey of program directors and chief residents. Headache. 2016;56:871-877.
15.
ACGME Program Requirements for Graduate Medical Education in Child Neurology. 2023.
16.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1-211.
17.
HersheyAD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol.2010;9:190-204.
18.
RicherLBillinghurstLLinsdellMA, et al.Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev.2016;4:CD005220.
19.
OskouiMPringsheimTBillinghurstL, et al.Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93:500-509.
20.
LoderEBurchRRizzoliP. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930-945.
21.
PowersSWCoffeyCSChamberlinLA, et al; CHAMP Investigators. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376:115-124.
22.
ShahSCalderonM-DCrainNPhamJRinehartJ. Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population. Reg Anesth Pain Med. 2021;46:41-48.
23.
WinnerPKKabboucheMYonkerMWangsadipuraVLumABrinMF. A randomized trial to evaluate onabotulinumtoxinA for prevention of headaches in adolescents with chronic migraine. Headache. 2020;60:564-575.
24.
LindsayRKalifaAKuziekJKabboucheMHersheyADOrrSL. The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: a systematic review and meta-analysis. Headache. 2024;64:1200-1216.
25.
RobbinsMSRobertsonCEAilaniJLevinMFriedmanDIDodickDW. Procedural headache medicine in neurology residency training: A survey of US program directors. Headache. 2016;56:79-85.
26.
SzperkaCLVanderPluymJOrrSL, et al.Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache. 2018;58:1658-1669.
